STROSutro Biopharma, Inc.

21.04USD-3.97%Mkt Cap: 348.87M $P/E:

Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, Xpr…

Key Statistics

Company
Market Cap348.87M $
Enterprise Value197.29M $
Revenue (TTM)45.70M $
Gross Profit-99.04M $
Net Income (TTM)-191.09M $
Revenue/Share3.915 USD
Last Price21.04 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees128
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-3.41
PEG
EV/EBITDA-1.57
EV/Revenue4.32
P/S7.68
P/B-5.24
EPS (TTM)-16.87
EPS (Forward)-6.21
52W Range
7.15038% of range43.85
52W High43.85 USD
52W Low7.150 USD
Profitability
Gross Margin-216.71%
Oper. Margin-301.73%
EBITDA Margin-275.25%
Profit Margin-186.45%
ROE144.27%
ROA-109.93%
Growth
Revenue Growth-84.60%
Earnings Growth
Cash Flow & Leverage
Operating CF-177.23M $
CapEx (TTM)1.70M $
FCF Margin-220.46%
FCF Yield-28.88%
Net Debt-153.56M $
Net Debt/EBITDA1.22
Balance Sheet
Debt/Equity-0.12
Current Ratio3.32
Quick Ratio3.22
Book Value/Sh-4.0370 USD
Cash/Share9.912 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split1:10
Split DateDec 3, 2025
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.23 USD
Upside (mean)+124.5%
Target Range10.00 USD61.00 USD
$10.00+124.5% to mean$61.00
# Analysts13
Ownership
Shares Out.16.58M
Float10.77M
Insiders2.26%
Institutions98.57%
Short Interest
Short Ratio5.4d
Short % Float10.56%
Short % Out.10.53%
Shares Short1.74M
Short (prev mo.)1.36M
Technical
SMA 5026.39 (-20.3%)
SMA 20021.61 (-2.7%)
Beta1.51
S&P 52W Chg18.16%
Avg Vol (30d)292.99K
Avg Vol (10d)400.26K
Technical Indicators
RSI (14)37.7
MACD-1.3599
MACD Signal-1.2034
MACD Hist.-0.1565
BB Upper26.85 USD
BB Middle23.54 USD
BB Lower20.23 USD
BB Width28.11%
ATR (14)2.011 USD
Vol Ratio (20d)0.66x